NEW YORK – Swedish diagnostics firm Immunovia said on Thursday that it has received a clinical and public health laboratory license from the California Department of Public Health. The new license will allow Californian physicians to order Immunovia's Immray PanCan-d test for patients.
Lund-based Immunovia has been rolling out the antibody microarray-based test for early-stage pancreatic cancer detection on a state by state basis in the US. The assay is offered as a laboratory-developed test via Immunovia's CLIA-compliant facility in Marlborough, Massachusetts.
Immunovia obtained a similar license in Massachusetts last year, and this year obtained licenses in Rhode Island, Pennsylvania, and Maryland.
PanCan-d is a blood-based multiplexed test that relies on eight markers associated with immunoregulation and pancreatic tumors. The test can gauge the concentration of the markers in patient blood by measuring signal intensities on the array.